{"id":45175,"date":"2025-10-29T17:24:43","date_gmt":"2025-10-29T09:24:43","guid":{"rendered":"https:\/\/flcube.com\/?p=45175"},"modified":"2025-10-29T17:24:44","modified_gmt":"2025-10-29T09:24:44","slug":"iaso-biotherapeutics-partners-with-gc-cell-to-advance-equecabtagene-autoleucel-car%e2%80%91t-therapy-in-south-korea","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45175","title":{"rendered":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>IASO Biotherapeutics<\/strong>, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with <strong>GC Cell Co.,\u202fLtd.<\/strong> to bring its BCMA\u2011targeted CAR\u2011T cell therapy <strong>Equecabtagene Autoleucel<\/strong> to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-highlights\"><strong>Collaboration Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint Development &amp; Commercialization<\/strong> \u2013 The partnership will progressively drive the full regulatory and commercial lifecycle of Equecabtagene Autoleucel in South Korea.<\/li>\n\n\n\n<li><strong>Regulatory Milestones<\/strong> \u2013 The therapy has already received <strong>Orphan Drug Designation<\/strong> from the South Korean Ministry of Food and Drug Safety (MFDS) and was further designated as a <strong>Fast\u2011Track Advanced Regenerative Therapy<\/strong> in August\u202f2025.<\/li>\n\n\n\n<li><strong>Strategic Alignment<\/strong> \u2013 The deal positions GC\u202fCell as the local commercial partner while leveraging IASO\u2019s proven clinical platform and regulatory experience.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-equecabtagene-autoleucel\"><strong>Product Profile \u2013 Equecabtagene Autoleucel<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 A BCMA\u2011targeted CAR\u2011T cell therapy independently developed by IASO, designed to eradicate malignant plasma cells in multiple myeloma patients.<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong> \u2013 Approved for market by China\u2019s National Medical Products Administration (NMPA) in June\u202f2023.<\/li>\n\n\n\n<li><strong>Clinical Development<\/strong> \u2013 Ongoing clinical data support its efficacy and safety profile, positioning it as a promising first\u2011in\u2011class therapy in the rapidly expanding CAR\u2011T market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact\"><strong>Strategic Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong> \u2013 The collaboration opens a new growth avenue for IASO in the Korean biopharma landscape, while GC\u202fCell expands its oncology portfolio with a cutting\u2011edge CAR\u2011T product.<\/li>\n\n\n\n<li><strong>Accelerated Access<\/strong> \u2013 Fast\u2011Track designation and orphan status are expected to streamline the approval process, potentially delivering therapy to patients sooner.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,21,77,4414,594],"class_list":["post-45175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-car-t","tag-cell-therapy","tag-gc-cell","tag-iaso-biotherapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45175\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea\" \/>\n<meta property=\"og:description\" content=\"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45175\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T09:24:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T09:24:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea\",\"datePublished\":\"2025-10-29T09:24:43+00:00\",\"dateModified\":\"2025-10-29T09:24:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175\"},\"wordCount\":297,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2909.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"GC Cell\",\"IASO Biotherapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45175#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45175\",\"name\":\"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2909.webp\",\"datePublished\":\"2025-10-29T09:24:43+00:00\",\"dateModified\":\"2025-10-29T09:24:44+00:00\",\"description\":\"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45175\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2909.webp\",\"width\":1080,\"height\":608,\"caption\":\"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45175#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea - Insight, China&#039;s Pharmaceutical Industry","description":"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45175","og_locale":"en_US","og_type":"article","og_title":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea","og_description":"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.","og_url":"https:\/\/flcube.com\/?p=45175","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T09:24:43+00:00","article_modified_time":"2025-10-29T09:24:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45175#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45175"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea","datePublished":"2025-10-29T09:24:43+00:00","dateModified":"2025-10-29T09:24:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45175"},"wordCount":297,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","keywords":["Cancer","CAR-T","Cell-therapy","GC Cell","IASO Biotherapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45175#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45175","url":"https:\/\/flcube.com\/?p=45175","name":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45175#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","datePublished":"2025-10-29T09:24:43+00:00","dateModified":"2025-10-29T09:24:44+00:00","description":"IASO Biotherapeutics, a China\u2011based biotherapeutics developer, today announced a strategic collaboration agreement with GC\u202fCell Co.,\u202fLtd. to bring its BCMA\u2011targeted CAR\u2011T cell therapy Equecabtagene Autoleucel to the South Korean market for the treatment of multiple myeloma. GC\u202fCell will spearhead the registration, regulatory approval, and commercialization of the product in South Korea.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45175#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45175"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45175#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","width":1080,"height":608,"caption":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45175#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IASO Biotherapeutics Partners with GC\u202fCell to Advance Equecabtagene Autoleucel CAR\u2011T Therapy in South Korea"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45175"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45175\/revisions"}],"predecessor-version":[{"id":45188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45175\/revisions\/45188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45187"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}